Where does 1ST Biotherapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), 1ST Biotherapeutics, Inc. ranks #25,614 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does 1ST Biotherapeutics, Inc. hold?

1ST Biotherapeutics, Inc. holds 10 US utility patents granted between 2019 and 2025, spanning 5 technology areas.

What is 1ST Biotherapeutics, Inc.'s Innovation Score?

1ST Biotherapeutics, Inc. has an Innovation Score of 34.3 out of 100 (47th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does 1ST Biotherapeutics, Inc. focus on?

1ST Biotherapeutics, Inc.'s top technology area is C07D (Heterocyclic Compounds) with 10 patents, ranking #819 of 3,165 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

Is 1ST Biotherapeutics, Inc.'s patent grant rate increasing or decreasing?

1ST Biotherapeutics, Inc.'s recent grant velocity is +600% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for 1ST Biotherapeutics, Inc.'s patents?

1ST Biotherapeutics, Inc.'s patents average 19.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the 1ST Biotherapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

1ST Biotherapeutics, Inc.

USPTO PatentsView assignee record - 10 granted patents across 5 technology areas, recorded in grant years 2019–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, 1ST ranks #25,614 of 49,997 tracked US assignees by granted-patent volume, with 10 patents across 5 technology areas.

#25,614
of 49,997 US assignees by volume: 47th percentile
by Innovation Score (34.3/100): 19.0
avg claims per patent: +600%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R25614 · Foreign Corporation #25,614 · 10 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 10 grants
MID-PACK #25,614/49,997
PHOTO-FINISH 15 Seconds of Fame
CPC-NARROW C07D · 5 areas
INNOV-THIN 34.3/100
CLAIMS-RICH 19.0 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +600% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: 15 Seconds of Fame, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How 1ST’s 34.3 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 8.3 pts (24%) Velocity 6.7 pts (20%) Breadth 7.9 pts (23%) Claim depth 11.4 pts (33%)

Qualcomm Incorporated · highest

85
1ST Biotherapeutics · this assignee

34
3D Lighting… · lowest

7

What this shows 1ST's Innovation Score is 34.3/100 (47th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for 1ST?

Each dot is one of 1ST’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). 1ST’s own 19.0 claims/patent is ABOVE the 17.1 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

1ST vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where 1ST's grants concentrate

1ST Biotherapeutics, Inc. is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2023 (4 grants) versus a trough of 1 in 2019. By volume, 1ST sits between priceline.com LLC and 410 Medical, Inc..

1ST's three-year grant acceleration

1ST Biotherapeutics, Inc. shows 4 grants in 2022–2024 against only 4 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

priceline com

11
15 Seconds of Fame

10
1globe Biomedical

10
1Q

10
1st Defence Indus…

10
2nd Skull

10
3D Plus

10
410 Medical

10
1ST Biotherapeuti… ◀

10

What this shows 1ST holds 10 patents at rank #25,614, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near 1ST

By rank, the assignees closest to #25,614 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in 1ST's primary technology class.

1ST's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

34 47th percentile higher than 47% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table

1ST Biotherapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2019	1	10.0%
2020	1	10.0%
2021	2	20.0%
2023	4	40.0%
2025partial year	2	20.0%

Which technologies does 1ST Biotherapeutics, Inc. patent most?

C07D - Heterocyclic Compounds 10

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 8

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 6

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 4

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 3

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

1ST Biotherapeutics, Inc.'s patent record in context - here's where to go next.

1ST Biotherapeutics, Inc.'s lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
Ranked #25,614 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare 1ST Biotherapeutics, Inc. against priceline.com LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 34.3/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.